ArisGlobal acquires Boehringer Ingelheim’s signal analytics technology
This digital innovation represents impactful progress industry-wide, as it opens an opportunity for many life sciences organisations to advance their pharmacovigilance analytics and insights
Boehringer Ingelheim and ArisGlobal recently announced the acquisition of Boehringer Ingelheim’s digital innovation, BRASS, by ArisGlobal. This data insights engine will be integrated into ArisGlobal’s technology platform, LifeSphere, under the name of LifeSphere Clarity, and will play a key role in driving industry-wide advancement of pharmacovigilance and patient safety, Boehringer Ingelheim notified in a statement.
LifeSphere Clarity is an intelligent signal analytics technology that provides insights which are otherwise challenging or impossible to find. Jointly developed by Boehringer Ingelheim’s Patient Safety and Technology teams, the digital engine leverages automation and Artificial Intelligence (AI) to consolidate patient safety data, reveals possible reasons why things happened, and allows modelling the possible impact of different influences, the statement said.
Robert Buchberger, Head, Patient Safety and Pharmacovigilance, Boehringer Ingelheim, said in the statement, “At Boehringer Ingelheim, we always put the patients first. BRASS (soon to become LifeSphere Clarity) is a system that can help a pharma company understand the whole network of how diseases, comorbidities, effects and side effects of medications, as well as medical events influence each other. The ambition is to ensure that each patient gets the best and safest therapy option for them, and robust and rapid benefit-risk assessment also helps get the right therapies to patients faster.
In addition, Markus Schümmelfeder, Head, IT, Boehringer Ingelheim, said, “We are pleased to be building on our partnership with ArisGlobal to make this innovative technology accessible for the benefit of patients.”
Once integrated into the LifeSphere platform, users will be presented with valuable connections and gain deeper insights, faster. Making this tool available within the LifeSphere platform will harness the user community’s input to make better automated suggestions on possible causal patterns influencing adverse events. Ultimately, this will give the safety specialist user within a pharma company the ability to create a more efficient medical benefit-risk analysis. This informative technology will advance ArisGlobal’s LifeSphere Data and Analytics initiative, delivering complementary capabilities to LifeSphere Signal and Risk Management as one example of the application for the technology, the statement further said.
This digital innovation represents impactful progress industry-wide, as it opens an opportunity for many lifesciences organisations to advance their pharmacovigilance analytics and insights. It is also representative of the power of partnership across the lifesciences industry, as Boehringer Ingelheim and ArisGlobal have worked collaboratively for over three decades, continually striving for, and achieving, pharmacovigilance innovation, the statement concluded.